Paraoxonase Genes and Disease

References

• Primo-Parmo S L, Sorenson R C, Teiber J, La Du B N. The human serum paraoxonase/aryiesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498–509
   PubMed Web of Science ®Google Scholar
• Tsui L C, Buchwald M, Barker D, Braman J C, Knowlton R, Schumm J W, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985; 230: 1054–7
   PubMed Web of Science ®Google Scholar
• Mackness M I. Possible medical significance of human serum paraoxonase. Enzymes Hydrolysing Organophosporus Compounds, E Reiner, W N Aldridge, F CG Hoskin. Ellis-Horwood, ChichesterUK 1989; 202–13
   Google Scholar
• Mackness M I, Arrol S, Durrington P N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152–4
   PubMed Web of Science ®Google Scholar
• Mackness M I, Durrington P N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243–53
   PubMed Web of Science ®Google Scholar
• Mackness M I, Arrol S, Abbott C A, Durrington P N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129–35
   PubMed Web of Science ®Google Scholar
• Watson A D, Berliner J A, Hama S Y, La Du B N, Fault K F, Fogelman A M, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882–91
   PubMed Web of Science ®Google Scholar
• Watson A D, Leitinger N, Navab M, Faull K F, Horkko S, Witztum J L, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272: 13597–607
   PubMed Web of Science ®Google Scholar
• Watson A D, Navab M, Hama S Y, Sevanian A, Prescott S M, Stafforini D M, et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 95: 774–82
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier C L, Newton R S, Primo-Parmo S L, La Du B N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101: 1581–90
   PubMed Web of Science ®Google Scholar
• Shih D M, Gu L, Hama S, Xia Y-R, Navab M, Fogelman A M, et al. Genetic-dietary regulation of serum paraxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630–9
   PubMed Web of Science ®Google Scholar
• Shih D M, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organo-phosphate toxicity and atherosclerosis. Nature 1998; 394: 284–7
   PubMed Web of Science ®Google Scholar
• Adkins S, Gan K N, Mody M, La Du B N. Molecular basis for the polymorphic forms of human serum paraoxonase/aryiesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598–608
   PubMed Web of Science ®Google Scholar
• Humbert R, Adler D A, Disteche C M, Hassett C, Omiecinski C J, Furlong C E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73–6
   PubMed Web of Science ®Google Scholar
• Mackness M I, Patel B, Durrington P N, Connelly P W, Hegele R A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69–76
   PubMed Web of Science ®Google Scholar
• Davies H G, Richter R J, Keifer M, Broomfield C A, Sowalia J, Furlong C E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334–6
   PubMed Web of Science ®Google Scholar
• Blatter-Garin M-C, James R W, Dussoix P, Blanche H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99: 62–6
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness M I, Arrol S, Turkie W, Durrington P N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998; 423: 57–60
   PubMed Web of Science ®Google Scholar
• Ruiz J, Blanche H, James R W, Blatter-Garin M-C, Vaise C, Charpentier G. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869–72
   PubMed Web of Science ®Google Scholar
• Serrato M, Marian A J. A variant of human paraoxonase/aryiesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005–8
   PubMed Web of Science ®Google Scholar
• Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257–60
   PubMed Web of Science ®Google Scholar
• Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. The 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vase Biol 1997; 17: 3565–9
   PubMed Web of Science ®Google Scholar
• Sanghera D K, Saha N, Aston C E, Kamboh M I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vase Biol 1997; 17: 1067–73
   PubMed Web of Science ®Google Scholar
• Herrmann S M, Blanche H, Poirier O, Arveiter D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996; 126: 299–304
   PubMed Web of Science ®Google Scholar
• Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98: 883–5
   PubMed Web of Science ®Google Scholar
• Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57: 69–73
   Google Scholar
• Lansbury A J, Calto A J, Carter A M, Bamford J M, Grant P J. The paraoxonase glutamine-arginine polymorphism and cerebrovascular disease. Cardiovasc Dis 1997; 7: 353–6
   Google Scholar
• Sanghera D K, Saha N, Kamboh M I. The codon 55 polymorphism of the paraoxonase 1 gene is not associated with risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136: 217–23
   PubMed Web of Science ®Google Scholar
• Mackness M I, Arrol S, Mackness B, Durrington P N. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997; 349: 851–2
   PubMed Web of Science ®Google Scholar
• Blatter M-C, James R W, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein K-45. Eur J Biochem 1993; 211: 871–9
   PubMedGoogle Scholar
• Saha N, Roy A C, Teo S H, Tay J SH, Ratnam S S. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40: 277–82
   PubMed Web of Science ®Google Scholar
• Mackness M I, Harty D, Bhatnagar D, Winocour P H, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193–9
   PubMed Web of Science ®Google Scholar
• Pavkovic E, Simeon V, Reiner E, Suck M, Lipovac V. Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders. Chem Biol Interact 1993; 87: 179–82
   PubMed Web of Science ®Google Scholar
• Hegele R A, Brunt J H, Connelly P W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Throtnb Vase Biol 1995; 15: 89–95
   PubMed Web of Science ®Google Scholar
• Hegele R A, Brunt J H, Connelly P W. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vase Biol 1995; 15: 861–71
   PubMed Web of Science ®Google Scholar
• Hegele R A, Connelly P W, Hanley A J, Sun F, Harris S B, Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vase Biol 1997; 17: 1060–6
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Scherer S W, Xi T, Nickle D C, Majer M, Huizenga J J, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998; 213: 149–57
   PubMed Web of Science ®Google Scholar
• Sanghera D K, Aston C E, Saha N, Kamboh M I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62: 36–44
   PubMed Web of Science ®Google Scholar
• Hegele R A, Harris S B, Connelly P W, Hanley A J, Tsui L C, Zinman B, et al. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin Genet 1998; 54: 394–9
   PubMedGoogle Scholar
• Boright A P, Connelly P W, Brunt J H, Scherer S W, Tsui L C, Hegele R A. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 1998; 139: 131–6
   PubMed Web of Science ®Google Scholar
• Hegele R A, Connelly P W, Scherer S W, Hanley A J, Harris S B, Tsui L C, et al. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 3373–7
   PubMed Web of Science ®Google Scholar
• Hegele R A, Connelly P W, Scherer S W, Hanley A J, Harris S B, Tsui L C, et al. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet 1997; 350: 785
   PubMedGoogle Scholar
• Busch C P, Ramdath D D, Ramsewak S, Hegele R A. Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics
   Google Scholar
• Barker D JP. The fetal and infant origins of disease. Eur J Clin Invest 1995; 25: 457–63
   PubMed Web of Science ®Google Scholar
• Dhawan J. Coronary heart disease risks in Asian Indians. Curr Opin Lipidol 1996; 7: 196–8
   PubMedGoogle Scholar
• Stein C E, Fall C HD, Kumaran K, Osmond C, Cox V, Barker D JP. Fetal growth and coronary heart disease in South India. Lancet 1996; 384: 1269–73
   Google Scholar
• Dunger D B, Ong K KL, Huxtable S J, Sherriff A, Woods K A, Ahmed M L, et al. Association of the INS VNTR with size at birth. Nat Genet 1998; 19: 98–100
   PubMed Web of Science ®Google Scholar